JNJ's strong fundamentals include 25.74% ROE and 21.48% profit margin, indicating efficient capital use and operational excellence. The company's defensive nature is confirmed by a low beta of 0.235, making it suitable for risk-averse portfolios during market volatility. Technical indicators show price trading above key moving averages (200 SMA at $238.26, 50 SMA at $264.28), confirming a bullish trend. The Forward P/E of 22.34 offers a discount compared to TTM P/E of 31.50, suggesting potential value for growth-focused investors. Recent positive pipeline developments, including RYBREVANT survival data and Tremfya Phase 4 success, strengthen JNJ's therapeutic portfolio.

The PEG ratio of 2.84 suggests potential overvaluation relative to growth, cautioning against buying at current levels. The MACD histogram shows declining momentum (-0.26), indicating slowing upward momentum and potential near-term consolidation. A current ratio of 1.09 is marginally tight, raising concerns about short-term liquidity for aggressive credit analysts. Rising Treasury yields (10Y at 5.18%) pressure high valuation stocks like JNJ, which trades at a rich P/E of 31.50 TTM. Patent cliff risks and litigation exposure, noted in news coverage, present potential headwinds to future growth.

Johnson & Johnson

JNJ· NYQ· Healthcare· Drug Manufacturers - General

$271.19

+0.19% Delayed prices.

Johnson & Johnson (JNJ) Stock Analysis: Hold Amid Strong Fundamentals

Published on Sep 26, 2026· Produced by the AI agent research team

Johnson & Johnson (JNJ) maintains a Hold rating due to strong fundamentals, defensive positioning, and technical indicators. The company demonstrates robust profitability with a 25.74% ROE and 21.48% profit margin, supported by a 1.98% dividend yield. Technical analysis shows price above key moving averages but with weakening momentum, suggesting caution for new buyers.

Verified: 12 of 12 checks passedVerification report

Before publication, every analysis passes automatic checks: every figure and source is cross-checked against market data and the analyst reports.

Decision and data · 6/6

Data coverage
All 4 analyst reports (market, fundamentals, news and sentiment) are available and complete.
Data freshness
Closing prices from 2026-09-25, 1 day(s) from the analysis date (2026-09-26); the maximum allowed is 5.
Market data cross-check
4 figure(s) in the reports (P/E, margins, market cap, 52-week range, prices) match real market data.
Valid rating
The final decision issues a valid rating on the five-level scale: Hold.
Decision figures
All 3 figures in the final decision appear in the market data or the analyst reports.
Decision sources
The decision cites no source, study or entity outside the analysed data.
Claims discarded from the debate
During the agents' debate 8 unsupported figure(s) were mentioned (Abbotts, Affairs, Competitor, Overvalued, Social, World); they were discarded and are not used in the decision or the article.

Automatically corrected 1 time(s) before passing verification.

Article · 6/6

Rating consistency
The article states exactly the decided rating (Hold).
Article figures
All 30 figures in the article appear in the market data or the analyst reports.
Article sources
The article cites no source, study or entity outside the analysed data.
Language
The text is written 100% in the article's language, with no untranslated terms.
Structure
672 words, 5 sections, 5 bull points, 5 bear points and 5 risks; title and description within limits.
Tone
Balanced language, with no promised returns or promotional expressions.

Bull case

JNJ's strong fundamentals include 25.74% ROE and 21.48% profit margin, indicating efficient capital use and operational excellence.
The company's defensive nature is confirmed by a low beta of 0.235, making it suitable for risk-averse portfolios during market volatility.
Technical indicators show price trading above key moving averages (200 SMA at $238.26, 50 SMA at $264.28), confirming a bullish trend.
The Forward P/E of 22.34 offers a discount compared to TTM P/E of 31.50, suggesting potential value for growth-focused investors.
Recent positive pipeline developments, including RYBREVANT survival data and Tremfya Phase 4 success, strengthen JNJ's therapeutic portfolio.

Bear case

The PEG ratio of 2.84 suggests potential overvaluation relative to growth, cautioning against buying at current levels.
The MACD histogram shows declining momentum (-0.26), indicating slowing upward momentum and potential near-term consolidation.
A current ratio of 1.09 is marginally tight, raising concerns about short-term liquidity for aggressive credit analysts.
Rising Treasury yields (10Y at 5.18%) pressure high valuation stocks like JNJ, which trades at a rich P/E of 31.50 TTM.
Patent cliff risks and litigation exposure, noted in news coverage, present potential headwinds to future growth.

Risks

Rising interest rates could pressure JNJ's high price-to-book ratio (7.69x).
Regulatory risks in the pharmaceutical sector, including drug pricing reforms, may impact profitability.
The company's PEG ratio of 2.84 suggests overvaluation relative to growth, requiring careful valuation assessment.
A potential downward breakout below the Bollinger Lower Band ($262.83) could signal weakening momentum.
Litigation exposure, including opioid and infrastructure suits, remains a persistent risk factor.

Overview

Johnson & Johnson (JNJ) continues to demonstrate strong fundamentals as a healthcare leader in pharmaceuticals, medical devices, and consumer healthcare products. The company operates in a sector that has shown resilience amid market volatility, supported by JNJ's defensive characteristics and diversified portfolio. As of September 25, 2026, JNJ trades at $271.22 with a market capitalization of $653.6 billion, reflecting its position as a large-cap healthcare leader.

Technical picture

JNJ's technical picture shows a strong bullish trend as of September 25, 2026. The stock price is trading significantly above both its long-term (200 SMA) and medium-term (50 SMA) moving averages, with price at $271.22 compared to 200 SMA at $238.26 (13.8% above) and 50 SMA at $264.28 (2.6% above). The short-term momentum (10 EMA) is at $269.64, with price just 0.6% above this level. However, the MACD histogram shows declining momentum (-0.26), indicating slowing upward momentum and potential near-term consolidation. The RSI remains neutral at 57.23, suggesting no immediate overbought conditions. The ATR (5-day) of $5.16 provides a clear stop-loss level at $266.06 (271.22 - 5.16), which serves as a key technical support level.

Fundamentals

JNJ's fundamentals remain strong, with a 25.74% return on equity (ROE) and 21.48% net profit margin, reflecting efficient capital use and operational excellence. The company generates substantial free cash flow of $16.89 billion, supporting its 1.98% dividend yield and sustainable dividend policy. The forward P/E of 22.34 represents a significant discount to the TTM P/E of 31.50, suggesting market optimism about near-term earnings growth. However, the PEG ratio of 2.84 suggests potential overvaluation relative to growth, requiring careful assessment. JNJ's balance sheet shows moderate leverage with a debt-to-equity ratio of 57.71%, and a current ratio of 1.09, which is acceptable for a large-cap healthcare firm but slightly tight for aggressive short-term credit analysis.

News and sentiment

Recent news highlights JNJ's strong pipeline developments, including positive long-term survival data for RYBREVANT in lung cancer treatment, Phase 4 success for Tremfya in axial psoriatic arthritis, and a patent win for Spravato. These developments strengthen JNJ's therapeutic portfolio and reduce reliance on legacy products. The company is also advancing talks with Apollo Global to divest its orthopedics unit for approximately $20 billion, which would accelerate JNJ's strategic focus on high-growth therapeutics. However, news coverage also notes legitimate risks including patent cliff risks and litigation exposure. Sentiment analysis shows a bullish score of 8.0/10, with StockTwits sentiment strongly bullish (53% bullish out of 30 messages) focused on potential acquisition activity, while news sentiment acknowledges both positive pipeline developments and risks like patent cliffs and litigation.

Bull vs bear debate

The bull case for JNJ centers on its strong fundamentals, defensive positioning, and technical indicators showing price above key moving averages. The company's 25.74% ROE and 21.48% profit margin demonstrate operational excellence, while the low beta of 0.235 confirms its defensive nature. The forward P/E discount of 22.34 compared to TTM P/E of 31.50 suggests potential value for growth-focused investors. However, the bear case highlights the PEG ratio of 2.84, which suggests overvaluation relative to growth, and the declining MACD momentum (-0.26), indicating slowing upward momentum. The current ratio of 1.09 is marginally tight, raising short-term liquidity concerns, and rising Treasury yields (10Y at 5.18%) pressure high valuation stocks like JNJ. The company's patent cliff risks and litigation exposure also present potential headwinds to future growth.

Verdict

Johnson & Johnson (JNJ) maintains a Hold rating due to its strong fundamentals, defensive positioning, and technical indicators. The company demonstrates robust profitability with a 25.74% ROE and 21.48% profit margin, supported by a 1.98% dividend yield. Technical analysis shows price above key moving averages but with weakening momentum, suggesting caution for new buyers. The forward P/E of 22.34 offers a discount compared to TTM P/E of 31.50, but the PEG ratio of 2.84 suggests potential overvaluation relative to growth. Investors should consider adding gradually as price remains above $266.06 (derived as last close $271.22 minus ATR $5.16), while remaining cautious about rising interest rates and potential patent-related risks.

Key metrics

Last close: $271.22
P/E (TTM): 31.5
Forward P/E: 22.34
Price / book: 7.69
Net margin: 21.5%
Revenue growth: 6.6%
ROE: 25.7%
Debt / equity: 57.71
Dividend yield: 2%
Beta: 0.24
52-week high: $281.07
52-week low: $179.80
Analyst mean target: $277.91

AI-generated informational content. Not financial advice or a personalised investment recommendation. Investing involves risk, including loss of capital.